Shimoda Biotech

Shimoda Biotech is a South African biotechnology company focused on enhancing the delivery and efficacy of established pharmaceutical compounds through cyclodextrin-based formulation technology. The company's lead product, Dyloject (diclofenac sodium), is an injectable non-steroidal anti-inflammatory drug (NSAID) developed for the treatment of acute pain in hospital settings. By utilizing cyclodextrins to improve drug solubility, Shimoda's technology allows for low-volume, rapid bolus injections that reduce the risk of injection-site reactions. Following its acquisition by Javelin Pharmaceuticals in 2005, the company's assets were eventually integrated into Hospira and subsequently Pfizer. Shimoda's expertise lies in the niche application of carbohydrate chemistry to solve complex drug formulation challenges.